Valeant Pharmaceuticals (VRX) will report results on November 8th before the market opens. Investors will watch for the following:
- Firm deal(s) on asset sales, including Salix and eye-surgery equipment division
- Progress of turnaround in key business areas, including B+L
- Progress of debt reduction schedule
B+L and its 'Naturelle' cosmetics:
Valeant must show its revenue growth is flat to positive. Any decline will trouble investors. The company has little room to raise drug prices. Before the Philidor exposure, VRX could increase drug prices in the double and triple digits...